Journal: Cell Death & Disease

Article Title: Oncogenic GALNT5 confers FOLFIRINOX resistance via activating the MYH9/ NOTCH/ DDR axis in pancreatic ductal adenocarcinoma

doi: 10.1038/s41419-024-07110-w

Figure Lengend Snippet: A–C Colony formation assays evaluating the proliferation difference of Patu8988 ( A ) and SW-1990 ( B ) experienced RNAi of GALNT5 treated with or without FOI (Three fields assessed per dish, three individual biological replicates performed, Two-way ANOVA, *** p < 0.001). FOI: the combination of 5-FU (4um), oxaliplatin (10um), and Irinotecan (10um) based on IC50 in WT PDAC cells, respectively. D Flow cytometry revealing the apoptosis difference of Patu8988 and SW-1990 experienced RNAi of GALNT5 treated with or without FOI (Three individual biological replicates performed, Two-way ANOVA, *** p < 0.001). ( E-F ) Flow cytometry revealing the cell cycle phase alteration difference of ( E ) Patu8988 and ( F ) SW-1990 experienced RNAi of GALNT5 treated with or without FOI (Three individual biological replicates performed, Two-way ANOVA, *** p < 0.001). G–J Oxaliplatin dose-response relationship curves were drawn and IC50 of oxaliplatin in the GALNT5 knockdown cell line ( G ) PATU8988 and (H)SW1990 and overexpression cell line ( I ) MiaPaca-2 and ( J ) PANC1 were calculated. K–N Oxaliplatin dose-response relationship curves were drawn and IC50 of oxaliplatin in the GALNT5 knockdown cell line ( K ) PATU8988 and ( L ) SW1990 and overexpression cell line ( M ) MiaPaca-2 and ( N ) PANC1 were calculated. Q–R statistics analysis of IC50 differences demonstrating IC50 alterations of (O-P) oxaliplatin and Q – R Irinotecan when GALNT5 was knocked down or overexpressed. (Three individual biological replicates performed, Two-way ANOVA, ** *p < 0.001). S–T IC50 alteration fold change showing differences between degrees of oxaliplatin and Irinotecan IC50 in cell lines treated with GALNT5 knockdown and overexpression. (Three individual biological replicates performed, Two-way ANOVA, *** p < 0.001).

Article Snippet: FOI is the combination of 5-fluorouracil (10uM), oxaliplatin(8uM), and irinotecan (8uM) in vitro experiments based on IC50 in WT PDAC cells respectively, and Concentrations of 5-fluorouracil (23 mg/kg), oxaliplatin(10 mg/kg), irinotecan(100 mg/kg) for in vivo experiments (i.p) according to manufacturer’s instructions (5-FU, #HY-90006; oxaliplatin, #HY-17371; irinotecan, #HY-16562, MCE).

Techniques: Flow Cytometry, Knockdown, Over Expression